Review
Oncology
Yajing Zhu, Evangelos Tzoras, Alexios Matikas, Jonas Bergh, Antonios Valachis, Ioannis Zerdes, Theodoros Foukakis
Summary: This meta-analysis reveals the dynamics of TILs during NAT for breast cancer and suggests prognostic implications of Delta TILs in TNBC. The longitudinal assessment of TILs during neoadjuvant therapy may have potential clinical utility.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Surbhi Bansil, Anthony Silva, Alana Taniguchi, Christina Wiedmer, Mayumi Fernandez, Ian Pagano, Koah Vierkoetter, Jeffrey Killeen, Jami Fukui
Summary: Tumor-infiltrating lymphocytes (TILs) have emerged as predictors of breast cancer treatment response and patient outcomes. This study provides preliminary data on the breast cancer tumor microenvironment for Asian and Native Hawaiian/Pacific Islander racial/ethnic groups, which are underrepresented in the literature.
Review
Oncology
Daniele Fanale, Alessandra Dimino, Erika Pedone, Chiara Brando, Lidia Rita Corsini, Clarissa Filorizzo, Alessia Fiorino, Maria Chiara Lisanti, Luigi Magrin, Ugo Randazzo, Tancredi Didier Bazan Russo, Antonio Russo, Viviana Bazan
Summary: In this review, the prognostic and predictive role of tumor-infiltrating lymphocytes (TILs) in ovarian cancer (OC) is discussed. Despite the immunogenic potential of OC, immunotherapy has not yielded expected results. Understanding factors influencing infiltration and the crosstalk between cancer and immune cells in the tumor microenvironment (TME) is crucial for unraveling heterogeneity in clinical outcomes. TILs have been recognized as clinically relevant markers for improved survival in OC, and may help identify OC patients who may benefit from immunotherapy.
Article
Oncology
Hongling Liang, Jia Huang, Xiang Ao, Weibang Guo, Yu Chen, Danxia Lu, Zhiyi Lv, Xiaojun Tan, Weixing He, Ming Jiang, Haoming Xia, Yongtao Zhan, Weiling Guo, Zhiqing Ye, Lei Jiao, Jie Ma, Changxi Wang, Hongsheng Li, Xuchao Zhang, Jianqing Huang
Summary: Immune characteristics, TMB, TCR, and TILs were simultaneously analyzed in breast cancer patients receiving neoadjuvant chemotherapy. Higher TMB and TCR diversity index were found in non-pCR patients compared to pCR patients, with a linear correlation between TMB and TCR. High TCR clonality and CD8+ expression were associated with disease-free survival, suggesting potential for guiding neo-adjuvant treatment in operable breast cancers.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Steven L. Morrison, Gang Han, Faith Elenwa, John T. Vetto, Graham Fowler, Stanley P. Leong, Mohammed Kashani-Sabet, Barbara A. Pockaj, Heidi E. Kosiorek, Jonathan S. Zager, Vernon K. Sondak, Jane L. Messina, Nicola Mozzillo, Schlomo Schneebaum, Dale Han
Summary: This multicenter retrospective study assessed the predictive and prognostic value of tumor-infiltrating lymphocytes (TILs) in melanoma. The study found that the presence of TILs predicted a negative sentinel lymph node biopsy and the absence of TILs may indicate worse survival in patients with a positive sentinel lymph node. TILs can also serve as a prognostic marker of survival when the sentinel lymph node status is not considered.
Article
Biochemistry & Molecular Biology
Jikun Feng, Jianxia Li, Xinjian Huang, Jiarong Yi, Haoming Wu, Xuxiazi Zou, Wenjing Zhong, Xi Wang
Summary: This study identified the clinicopathological factors related to TILs in breast cancer patients, constructed a nomogram to predict high density of TILs, and verified its efficiency in predicting treatment efficacy. The findings provide valuable insights for understanding tumor immunity and improving treatment strategies for breast cancer patients.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Review
Immunology
Biaoru Li
Summary: Tumor-infiltrating lymphocytes (TILs) play a key role in controlling and treating tumor diseases. Cultured TILs have been shown to effectively cure patients with melanoma. Our laboratory and clinicians have published numerous papers on TILs. Over the past 30 years, we have been studying the efficacy of TILs in treating solid tumors.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Anais Jimenez-Reinoso, Daniel Nehme-Alvarez, Carmen Dominguez-Alonso, Luis Alvarez-Vallina
Summary: Immunotherapy has shown effectiveness in treating various types of cancers, particularly with significant impact on patients with malignant tumors like melanoma. However, success in solid tumors remains limited and future challenges need to be addressed.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pathology
Xiangjie Sun, Jie Zhai, Baohua Sun, Edwin Roger Parra, Mei Jiang, Wencai Ma, Jing Wang, Anthony M. Kang, Kasthuri Kannan, Renganayaki Pandurengan, Shanyu Zhang, Luisa Maren Solis, Cara L. Haymaker, Maria Gabriela Raso, Julia Mendoza Perez, Aysegul A. Sahin, Ignacio I. Wistuba, Clinton Yam, Jennifer K. Litton, Fei Yang
Summary: Immune cell subtypes in TNBC, including PD-L1(+) tumor cells, total T cells, and effector/memory cytotoxic T cells, are promising prognostic biomarkers for overall survival. The study highlights the importance of phenotyping tumor immune cells using mIF for understanding the immune microenvironment in TNBC.
Article
Medicine, Research & Experimental
Guan-Hua Su, Yi Xiao, Lin Jiang, Ren-Cheng Zheng, He Wang, Yan Chen, Ya-Jia Gu, Chao You, Zhi-Ming Shao
Summary: This study demonstrated the feasibility of a radiomics model in predicting TILs status and provided a method to interpret the features, which could pave the way for precision medicine in TNBC.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Shiqi Li, Ying Zhang, Peigen Zhang, Shuijing Xue, Yu Chen, Lihua Sun, Rui Yang
Summary: Increased levels of TILs are associated with increased rates of response to NACT and improved prognosis for patients with TNBC and HER2-positive breast cancer. A threshold of 20% TILs is the most powerful outcome prognosticator of pCR.
Review
Immunology
Ruonan Li, Lili Cao
Summary: The treatment outcome of breast cancer is closely related to the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Triple-negative breast cancer (TNBC), which lacks expression of ER, PR, and HER2, has limited treatment options and a poor prognosis. Tumor-infiltrating lymphocytes (TILs) play a role in regulating breast cancer progression by affecting the tumor microenvironment. However, current treatments for TNBC, including surgery, chemotherapy, and radiotherapy, have not been satisfactory in terms of curative effects.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Teng Sun, Tong Wang, Xiangjun Li, Haibo Wang, Yan Mao
Summary: This study aimed to assess the prognosis of HER2-low-positive breast cancer in Chinese women and the predictive role of tumor-infiltrating lymphocytes (TILs). The results showed that high levels of TILs in HER2-low-positive breast cancer patients were associated with improved disease-free survival (DFS), especially in the HR (+)/HER2-low-positive subtype.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jenny Pousette, Annelie Johansson, Carolin Jonsson, Tommy Fornander, Linda S. Lindstrom, Hans Olsson, Gizeh Perez-Tenorio
Summary: The presence of immune cells within the tumor (TILs) does not have prognostic value for hormone-responsive breast cancer (ER+/HER2-). However, high expression of certain TIL markers indicates good prognosis and may be used for immunotherapy interventions after tamoxifen failure for ER+/HER2- subtype.
Article
Oncology
Kim R. M. Blenman, Michal Marczyk, Thomas Karn, Tao Qing, Xiaotong Li, Vignesh Gunasekharan, Vesal Yaghoobi, Yalai Bai, Eiman Y. Ibrahim, Tristen Park, Andrea Silber, Denise M. Wolf, Emily Reisenbichler, Carsten Denkert, Bruno V. Sinn, Mariya Rozenblit, Julia Foldi, David L. Rimm, Sibylle Loibl, Lajos Pusztai
Summary: This study examined gene expression, germline variant, and somatic mutation features associated with pathologic response to neoadjuvant durvalumab plus chemotherapy in basal-like triple-negative breast cancer. The results showed differences in gene expression and pathway enrichment between cases with different pathologic responses, with immune-rich cases being associated with macrophages, activated B cells, and T cells, while immune-poor cases were associated with other signaling pathways. The findings contribute to a better understanding and prediction of the efficacy of this treatment regimen.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Nelson Montalvo, Jorge Lara-Endara, Ligia Redroban, Maria Leiva, Christian Armijos, Leonardo Russo
Summary: Primary splenic histiocytic sarcoma is an extremely rare tumor of the hematopoietic system, with this case being the first reported with mutations in FLT3, NOTCH2, and KMT2A, along with associated hemophagocytic lymphohistiocytosis.
Article
Oncology
Leonardo Russo, Luis Betancourt, Gabriel Romero, Ali Godoy, Laura Bergamo, Rafael Delgado, Angela Ruiz, Marianna Gutierrez, Eduardo Salas, Maria Puzzi
ECANCERMEDICALSCIENCE
(2017)
Review
Oncology
Rafael Delgado Morales, Armando Gil Mendoza, Carmen Luces, Efren Bolivar Abreu, Gabriel Romero, Gabriel Perez, Leonardo Russo
ECANCERMEDICALSCIENCE
(2018)
Article
Oncology
Yuchao Liu, Zijia Liu, Liangyan Zhang, Yuelun Zhang, Ningchen Zhang, Yue Han, Le Shen
Summary: This study found an association between preoperative 6-min walk distance and postoperative complications in patients undergoing laparoscopic gastrointestinal cancer surgery.
Review
Oncology
Matteo Pavone, Rosa Autorino, Nicolo Bizzarri, Giuditta Chilorio, Vincenzo Valentini, Giacomo Corrado, Gabriella Ferrandina, Gabriella Macchia, Maria Antonietta Gambacorta, Giovanni Scambia, Denis Querleu
Summary: Ovarian transposition is an established method for protecting the ovaries from radiation, while surgical procedures for protecting the uterus are still under investigation. This study conducted a systematic review of uterine displacement techniques and performed dose simulation to assess the radiation dose received by the uterus. The results showed that the transposition approach was the most protective.
Article
Oncology
Silvia Ministrini, Maria Bencivenga, Federica Filippini, Gianni Mura, Carlo Milandri, Maria Antonietta Mazzei, Giulio Bagnacci, Mattia Berselli, Manlio Monti, Paolo Morgagni, Leonardo Solaini, Daniele Marrelli, Stefania Piccioni, Stefano De Pascale, Luigina Graziosi, Rossella Reddavid, Fausto Rosa, Claudio Belluco, Guido Tiberio
Summary: The Italian Research Group for Gastric Cancer developed a prospective database to evaluate the impact of a pragmatic attitude on the management of stage IV gastric cancer patients. The study found that different metastatic sites did not affect survival rates, but multiple metastatic sites were associated with worse survival. Patients who could undergo curative resection had better survival rates. A more accurate diagnostic workup and staging had a favorable impact on survival.
Article
Oncology
Luca Lambertini, Fabrizio Di Maida, Anna Cadenar, Samuele Nardoni, Antonio Andrea Grosso, Francesca Valastro, Pietro Spinelli, Riccardo Fantechi, Agostino Tuccio, Gianni Vittori, Andrea Mari, Lorenzo Masieri, Andrea Minervini
Summary: The aim of this study was to evaluate the functional outcomes of Florence intracorporeal neobladder (FloRIN) configuration technique performed with a stentless procedure. The results showed that the stentless procedure was associated with shorter console time and lower estimated blood loss compared to the stent group. There were no significant differences in terms of perioperative features and mid-term functional outcomes between the two groups.
Article
Oncology
Geun-Jeon Kim, Jooin Bang, Hyun-Il Shin, Sang-Yeon Kim, Dong -Il Sun
Summary: This study evaluated the outcome of tonsillar cancer managed with neoadjuvant chemotherapy followed by surgery. The results showed that neoadjuvant chemotherapy reduced tumor volume and pathological adverse features, significantly decreasing the need for adjuvant therapy. A greater reduction in tumor volume predicted a complete pathologic response. There was no significant difference in survival rates between the groups.
Article
Oncology
Alexandra Nassar, Stylianos Tzedakis, Ugo Marchese, Gaanan Naveendran, Remy Sindayigaya, Martin Gaillard, Francois Cauchy, Mickael Lesurtel, Brice Gayet, Olivier Soubrane, David Fuks
Summary: This study identified recurrence between the two stages and a larger tumor size in the future liver remnant as critical factors contributing to the failure of two-stage hepatectomy for bilobar colorectal liver metastases. These findings have important clinical implications for the selection and evaluation of TSH surgery.
Letter
Oncology
Michele Fiore, Gian Marco Petrianni, Gabriele D'Ercole, Pasquale Trecca, Sara Ramella
Review
Oncology
Harry Farrow, Oliver J. Pickering, James A. Gossage, Philip H. Pucher
Summary: The inclusion or exclusion of the thoracic duct in radical esophagectomy for esophageal cancer is a controversial issue. While removing the thoracic duct may increase lymph node yield, it may also lead to higher morbidity without any survival benefit.
Article
Oncology
Xiaokun Li, Siyuan Luan, Chi Zhang, Weili Kong, Xin Xiao, Haowen Zhang, Jianfeng Zhou, Yushang Yang, Yang Xu, Yong Qiang, Pinhao Fang, Yi Shen, Yong Yuan
Summary: This study proposes a new staging system based on ypTNM stage and cN status for early stage ESCC patients after nCRT. The new ypTNM-cN staging system demonstrates superior predictive ability and classification efficacy compared to the AJCC 8th ypTNM staging system. It provides new insights for accurately stratifying ypI stage ESCC patients.